British biotech company Sensyne Health has received regulatory approval in the UK for the first of a string of machine learning algorithms for Covid-19 risk prediction.
Technically redundant: Six-in-10 fear losing their jobs to AI
The programme, known under the codename of "SYNE-COV," analyses over 60 variables in the patient electronic health record to generate a prediction of the likelihood of a Covid-positive patient developing a severe disease - those requiring intensive care of excess ventilation.
Read more: The Rise of AI in 2021: Top Electronics & Tech Trends in Healthcare
The prediction, alongside solutions, are presented to doctors and health professionals to offer bespoke management options for patients admitted to hospitals with a Covid infection.
SYNE-COV was developed in collaboration with Chelsea & Westminster Hospitals NHS Foundation Trust and will now be offered to NHS Trusts across the UK.
It is the first algorithm of its kind to be given approval in the UK.
The UK has currently vaccinated around 15 million people, but active cases continue to be high.
The program could help alleviate some of the stress on healthcare services are facing before cases begin to plataeu.
The government hopes to have most people in the UK vaccinated by June 21 and is planning on slowly easing lockdown restriction between now and then.
Dominic Conlin, a hospital director for Chelsea and Westminster Hospital NHS Foundation Trust, said: “We’re excited by the possibilities this offers. This is individualised care by using patients’ own data to stratify risks and predict responses to clinical treatments, informing and supporting clinical decision making. This is a real step in taking forward digital innovation, data integration and analytics to enhance patient care in the NHS.”
Read more: maxon & Fourier Intelligence combine to transform rehabilitation tech
Lord Paul Drayson PhD, theCEO of Sensyne Health, said: “This is the first Sensyne Clinical AI algorithm to achieve regulatory approval that has been developed using our SENSE clinical AI platform.
"The SENSE engine is expected to be able to generate clinical algorithms across a range of medical conditions that will provide real-time clinical decision making support. Achieving the first regulatory approval is an important milestone for the Company and we look forward to being able to roll SYNE-COV out to the NHS.”
Back to Homepage
Back to Healthcare
Back to Technology & Innovation